June 24, 2019: Kennesaw, Georgia. Evonik has announced it will begin working with Perdue AgriBusiness to market its probiotic GutCare®, which supports a more balanced intestinal microbial population in the gut of poultry species and other monogastric animals.
Perdue AgriBusiness sources, merchandises and processes agricultural commodities. It also offers a diverse portfolio of products including grains, oilseeds, soybean meal, blended feed ingredients and top-quality seed oils for food and other uses.
The agreement for the US market starts a close technical cooperation between the two companies, and commercial activities are expected to begin immediately.
Ken O’Halloran, Vice President North America, Evonik, said: “This cooperative relationship will allow us to leverage the expertise of both companies to bring higher value offerings to our customers.”
George Betton, Vice President, Perdue AgriBusiness, added: “Our goal is to help customers prosper with flexible, forward-thinking solutions for agriculture-based products. We are excited to be working with Evonik to provide the best solutions for our customers.”
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2018, the enterprise generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.6 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around
€4.6 billion in 2018.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.